I read with interest the case report of a patient with lupus enteritis in the February 2021 issue of The Rheumatologist, and I thought the diagnostic approach and final diagnosis were very well presented; however, I noticed an omission which in my view is quite relevant to this patient’s overall management and to so many… [Read More]
Editor Keri Losavio has been a professional editor and writer in the medical and financial fields for 20 years and joined the Wiley team in February 2014. She has written for and edited newsletters, magazines, personal memoirs, book proposals, dissertations, textbooks and more.
Articles by Keri Losavio
‘Communication Is More Important Than Ever’: A Q&A with Howard M. Busch, DO
As founder and president of a large rheumatology group, Howard M. Busch, DO, says the pandemic has had a limited financial effect on many of the network’s clinics. Communication and technology have been key to adapting to the needs of patients and connecting with other providers during this critical time. ... [Read More]
Landmark Supreme Court Decision Supports States’ Rights to Regulate Pharmacy Benefit Managers
On Dec. 10, the Supreme Court of the United States of America (SCOTUS) issued a landmark decision in Rutledge, Attorney General of Arkansas, v. Pharmaceutical Care Management Association. In an 8–0 decision, the justices agreed that states have the right to impose regulations on pharmacy benefit managers (PBMs), companies that manage prescription drug benefits on… [Read More]
Reducing Immunogenicity of Pegloticase (RECIPE) with Concomitant Use of Mycophenolate Mofetil in Patients with Refractory Gout—a Phase II Double Blind Randomized Controlled Trial
Click here to view the visual abstract summaryBackground/Purpose: Pegloticase, a recombinant, pegylated uricase, is used for treatment of gout in patients who fail oral urate lowering therapy (ULT). Despite successful reduction of urate levels and flares, its use is limited due to immunogenicity, leading to infusion reactions.1 Co-administration of an immunomodulatory agent may mitigate this loss of efficacy and concern for drug-related… [Read More]
The End of the Beginning: COVID-19 Vaccines & Other Conundrums
“It’s like winning Powerball.” For months, there has been a steady trickle of questions from my patients, asking for my opinion about the new vaccines being developed to prevent COVID-19. More to the point, they want to know if they should be vaccinated. After some fits and starts, I finally struck upon a pat answer… [Read More]
Medicare’s Most Favored Nation Is My Least Favorite Notion!
In case you missed it, on Nov. 20, the Centers for Medicare & Medicaid Services (CMS), a department within the U.S. Department of Health and Human Services, announced that it will overhaul the payment system for Medicare Part B (i.e., infusion) drugs on Jan. 1, 2021. The plan is called the Most Favored Nation (MFN)… [Read More]
Dr. Blair Solow’s Picks for the Top RA Research Presented at ACR Convergence 2020
ACR CONVERGENCE 2020—Held Nov. 5–9, the ACR’s first fully virtual annual meeting provided participants with a vast repository of new research related to rheumatoid arthritis (RA). To help you sort through the noise, Elizabeth (Blair) Solow, MD, an assistant professor of medicine in the Division of Rheumatic Diseases at UT Southwestern Medical Center, Dallas, offered … [Read More]
Top Research in Lupus Presented at ACR Convergence 2020
ACR CONVERGENCE 2020—Held Nov. 5–9, the ACR’s first fully virtual annual meeting is a wrap, but that doesn’t mean it’s too late to catch the highlights. Dozens of research abstracts on various aspects of lupus were presented during the fully virtual event, and David S. Pisetsky, MD, PhD, professor of medicine and immunology at Duke… [Read More]
Dr. Ethan Craig Picks His Favorite Gout Abstracts from ACR Convergence 2020
In light of the release of the ACR’s new gout guideline, it’s not surprising that 50 abstracts of studies on various aspects of gout were accepted at ACR Convergence 2020. Here, we highlight just a few:... [Read More]
FAST Results for Febuxostat Safety in Gout Patients
ACR CONVERGENCE 2020—The results of a post-authorization study comparing the cardiovascular safety of febuxostat vs. allopurinol were presented in a late-breaking abstract session at the ACR’s fully virtual annual meeting on Monday, Nov. 9. Cardiologist Thomas MacDonald, MD, FRCP, MBChB, clinical professor (teaching and research) of molecular and clinical medicine, University of Dundee School of… [Read More]
- 1
- 2
- 3
- …
- 7
- Next Page »